MDACC Study No:2007-0730 ( NCT No: NCT00495066)
Title:A Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma. Protocol No. CA184-045
Principal Investigator:Wen-Jen Hwu
Treatment Agent:Ipilimumab
Study Status:Terminated
Study Description:The goal of this clinical research study is to give you a chance to receive
treatment with the drug BMS-734016 (ipilimumab).
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:N/A
Treatment Agents:Ipilimumab
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Bristol-Myers Squibb
Return Visit:- Screening Phase: 2 Days
- Induction Phase: every 3 weeks x 4
- Maintainance Phase: Every 12 weeks
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Wen-Jen Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults